The brevicidines represent a novel class of nonribosomal
antimicrobial
peptides that possess remarkable potency and selectivity toward highly
problematic and resistant Gram-negative pathogenic bacteria. A recently
discovered member of the brevicidine family, coined brevicidine B
(2), comprises a single amino acid substitution (from d-Tyr2 to d-Phe2) in the amino
acid sequence of the linear moiety of brevicidine (1)
and was reported to exhibit broader antimicrobial activity against
both Gram-negative (MIC = 2–4 μgmL–1) and Gram-positive (MIC = 2–8 μgmL–1) pathogens. Encouraged by this, we herein report the first total
synthesis of the proposed structure of brevicidine B (2), building on our previously reported synthetic strategy to access
brevicidine (1). In agreement with the original isolation
paper, pleasingly, synthetic 2 demonstrated antimicrobial
activity toward Escherichia coli, Pseudomonas
aeruginosa, and Klebsiella pneumoniae (MIC
= 4–8 μgmL–1). Interestingly, however,
synthetic 2 was inactive toward all of the tested Gram-positive
pathogens, including methicillin-resistant Staphylococcus
aureus strains. Substitution of d-Phe2 with its enantiomer, and other hydrophobic residues, yields analogues
that were either inactive or only exhibited activity toward Gram-negative
strains. The striking difference in the biological activity of our
synthetic 2 compared to the reported natural compound
warrants the re-evaluation of the original natural product for purity
or possible differences in relative configuration. Finally, the evaluation
of synthetic 1 and 2 in a human kidney organoid
model of nephrotoxicity revealed substantial toxicity of both compounds,
although 1 was less toxic than 2 and polymyxin
B. These results indicate that modification to position 2 may afford
a strategy to mitigate the nephrotoxicity of brevicidine.